Eshetu Atenafu
Overview
Explore the profile of Eshetu Atenafu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elliott M, Echelard P, Pipinikas C, Main S, Fuentes Antras J, Dou A, et al.
Nat Commun
. 2025 Feb;
16(1):1837.
PMID: 39984446
Circulating tumor DNA (ctDNA) is an emerging biomarker for the treatment of early breast cancer (EBC). We sought to evaluate a highly sensitive tumor-informed ctDNA assay in a real-world cohort...
2.
Manion K, Munoz-Grajales C, Kim M, Atenafu E, Faheem Z, Gladman D, et al.
Arthritis Rheumatol
. 2023 Dec;
76(5):726-738.
PMID: 38073017
Objective: The aim of this study was to determine the immunologic profile associated with disease flares in patients with systemic lupus erythematosus (SLE) and to investigate the clinical significance of...
3.
Remalante-Rayco P, Espiritu A, Daghistani Y, Chim T, Atenafu E, Keshavarzi S, et al.
Rheumatology (Oxford)
. 2023 Oct;
63(7):1980-1986.
PMID: 37792508
Objectives: The objectives of this study were to investigate the incidence of demyelinating disease (DD) among SpA patients and to identify risk factors that predict DD in this patient population....
4.
Al Nabhani I, Andrews C, Sibai J, Atenafu E, Young T, Chan S, et al.
EJHaem
. 2023 Feb;
4(1):232-235.
PMID: 36819167
PEG-asparaginase is used as a treatment for Philadelphia-negative acute lymphoblastic leukemia. In pediatric studies, triglycerides (TGs) were affected more by PEG-asparaginase than by native L-asparaginase (10.0% vs. 5.5%). We conducted...
5.
Zhao D, Eladl E, Zarif M, Capo-Chichi J, Schuh A, Atenafu E, et al.
Cancer Med
. 2022 Nov;
12(6):6511-6522.
PMID: 36394085
Background: Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) generally confers poor prognosis, however, patient outcomes are heterogeneous. The impact of TP53 allelic state and variant allele frequency (VAF) in AML-MRC...
6.
Cherniawsky H, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda V, et al.
Eur J Haematol
. 2021 Feb;
106(5):673-681.
PMID: 33539037
Objectives: To understand the impact of therapy sequencing on progression-free (PFS) and overall survival (OS) for the treatment of multiple myeloma (MM). The use of daily, low-dose, lenalidomide maintenance (LM)...
7.
Cherniawsky H, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda V, et al.
Haematologica
. 2020 Oct;
106(6):1733-1736.
PMID: 33054120
No abstract available.
8.
Hardisty M, Wright T, Campbell M, Burke M, Atenafu E, Cawricz M, et al.
Clin Exp Metastasis
. 2020 Jul;
37(5):575-584.
PMID: 32643007
Mechanical instability secondary to vertebral metastases can lead to pathologic vertebral compression fracture (VCF) mechanical pain, neurological compromise, and the need for surgical stabilization. Stereotactic body radiation therapy (SBRT) as...
9.
Detsky J, Nguyen T, Lee Y, Atenafu E, Maralani P, Husain Z, et al.
Neurosurgery
. 2020 May;
87(4):816-822.
PMID: 32374852
Background: Upon progression after upfront radiotherapy to spinal metastases, low-dose re-irradiation conventional external beam radiation (cEBRT) provides limited clinical benefit. Spine stereotactic body radiotherapy (SBRT) allows for dose escalation in...
10.
Faruqi S, Ruschin M, Soliman H, Myrehaug S, Zeng K, Husain Z, et al.
Int J Radiat Oncol Biol Phys
. 2020 Jan;
106(4):772-779.
PMID: 31928848
Purpose: Limited data exist quantifying the risk of adverse radiation effect (ARE) specific to hypofractionated stereotactic radiosurgery (HSRS). We present our analyses of the risk of ARE after 5 daily...